Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation

Journal of Andrology

Volumn 32, Issue 4, 2011, Pages 371-374

  Pierorazio, Phillip M ^a   Bivalacqua, Trinity J ^a   Burnett, Arthur L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; PHENYLEPHRINE; SILDENAFIL; ANILIDE; ANTIANDROGEN; NITRILE; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; ANTIANDROGEN THERAPY; ARTICLE; CASE REPORT; COLONOSCOPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ESOPHAGOSCOPY; FLUSHING; HUMAN; LABORATORY TEST; MALE; PRIAPISM; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; PENIS; VASCULARIZATION;

ANDROGEN ANTAGONISTS; ANILIDES; HUMANS; MALE; NITRILES; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PRIAPISM; PURINES; RECURRENCE; SULFONES; TOSYL COMPOUNDS;

EID: 80052620374     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.110.011890     Document Type: Article

References (23)

1. Abern MR, Levine LA. Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol. 2009;182:1401-1406.
2. Armagan A, Kim NN, Goldstein I, Traish AM. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl. 2006;27:517-526.
3. Bivalacqua TJ, Burnett AL. Priapism: new concepts in the pathophysiology and new treatment strategies. Curr Urol Rep. 2006;7:497-502.
4. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol. 2007;51:1732-1740.
5. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med. 2009;6:2494-2504.
6. Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, Champion HC, Burnett AL. Attenuated rhoA/rho-kinase signaling in penis of transgenic sickle cell mice. Urology. 2010;76:510.
7. Burnett AL. Therapy insight: priapism associated with hematologic dyscrasias. Nat Clin Pract Urol. 2005;2:449-456.
8. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am. 2007;34:631-642, viii.
9. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006a; 3:1077-1084.
10. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006b;67:1043-1048.
11. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102: 1661-1666.
12. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002;59(1):138.
13. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6:3274-3288.
14. Hwang TI, Lin YC. The relationship between hypogonadism and erectile dysfunction. Int J Impot Res. 2008;20:231-235.
15. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA. 2008;300:2638-2646.
16. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172:863-866.
17. Levine LA, Guss SP. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol. 1993;150:475-477.
18. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med. 2005;2:478-491.
19. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253-2263.
20. Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2:1274-1276.
21. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140:1861-1868.
22. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med. 2008;44:1506-1528.
23. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol. 2005;47:409-416.